Last update 25 Feb 2026

Laropiprant/Simvastatin/Nicotinic Acid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Laropiprant/niacin/simvastatin, MK-0524B, MK-524B
Target
HCAR3 x HMGCR x NIACR1 x PGD2 receptor
Action
agonists, inhibitors, antagonists
Mechanism
HCAR3 agonists(HM74 nicotinic acid GPCR agonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), NIACR1 agonists(Hydroxycarboxylic acid receptor 2 agonists)
Therapeutic Areas
Congenital DisordersEndocrinology and Metabolic Disease
Active Indication-
Inactive Indication
Hyperlipidemia, Familial CombinedHyperlipidemiasMixed hyperlipidemia+ [1]
Originator Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Active Organization-
Inactive Organization
Merck GmbHLaboratoires Merck Sharp & Dohme - Chibret SNCMerck & Co., Inc.Merck & Co., Inc.
+ [1]
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H19ClFNO4S
InChIKeyNXFFJDQHYLNEJK-CYBMUJFWSA-N
CAS Registry571170-77-9
View All Structures (3)

Related

7
Clinical Trials associated with Laropiprant/Simvastatin/Nicotinic Acid
NCT01294683
/ TerminatedPhase 3
A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
EUCTR2007-002516-26-AT
/ CompletedPhase 3
A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.
NCT00943124
/ CompletedPhase 1
An Open-Label, Definitive Bioequivalence Study to Compare the Pharmacokinetics of the Simvastatin, Nicotinic Acid, and MK0524 (Laropiprant) Components of a Formulation of MK0524B With That of Zocor™ and MK0524A Tablets
100 Clinical Results associated with Laropiprant/Simvastatin/Nicotinic Acid
Login to view more data
100 Translational Medicine associated with Laropiprant/Simvastatin/Nicotinic Acid
Login to view more data
100 Patents (Medical) associated with Laropiprant/Simvastatin/Nicotinic Acid
Login to view more data
100 Deals associated with Laropiprant/Simvastatin/Nicotinic Acid
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hyperlipidemia, Familial CombinedPhase 3-
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
01 Jan 2006
Mixed hyperlipidemiaPhase 3
Denmark
Merck & Co., Inc.Merck & Co., Inc.
23 Dec 2005
Primary hypercholesterolemiaPhase 3
Denmark
Merck & Co., Inc.Merck & Co., Inc.
23 Dec 2005
HyperlipidemiasPhase 3
United States
Merck GmbH
-
HyperlipidemiasPhase 3
Asia
Merck GmbH
-
HyperlipidemiasPhase 3
Australia
Merck GmbH
-
HyperlipidemiasPhase 3
Europe
Merck GmbH
-
HyperlipidemiasPhase 3
Mexico
Merck GmbH
-
HyperlipidemiasPhase 3
South America
Merck GmbH
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01294683 (0524B-118, CTgov)
Phase 3
Primary hypercholesterolemia
977
(Sequence 1: MK-0524B 2g/40g)
ftotupvxkg = ctnamyftbn lmxpkblgco (hsoiiiuiyp, jdjtvwyhby - wfykunijsy)
View more
-
13 Dec 2016
(Sequence 2: MK-0524A 2g + Simvastatin 40 mg)
ftotupvxkg = meywtiafgu lmxpkblgco (hsoiiiuiyp, aopnpfyebi - xdbswjxkkm)
View more
NCT00943124 (0524B-070, CTgov)
Phase 1
Dyslipidemias
220
simvastatin+MK0524B+laropiprant+ER Niacin
(MK0524B)
smpyiuycld(epxduleshy) = dyypzmgdgu tutejhmcfk (vvkeoovmea, 8.38)
View more
-
06 Jan 2010
(Simvastatin + MK0524A)
smpyiuycld(epxduleshy) = kvpehoydyg tutejhmcfk (vvkeoovmea, 7.78)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free